OncoMatch/Clinical Trials/NCT04767009
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Is NCT04767009 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy) for nsclc stage iv.
Treatment: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy) — Despite the impressive response rate to PD-1/PD-L1 immune checkpoint inhibitors, resistance inevitably develops in most patients. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy
Oligo-residual disease after effective treatment with PD-1/PD-L1 inhibitors
Cannot have received: tumor vaccine
Patients who have received tumor vaccine
Cannot have received: live, attenuated vaccine
Exception: Influenza vaccination is permitted only during influenza season, while live, attenuated influenza vaccine such as FluMist is not allowed.
administration of live, attenuated vaccine within 4 weeks before the start of treatment
Lab requirements
Blood counts
hemoglobin ≥80g/L, WBC ≥ 4.0 x 10^9/L or neutrophil count ≥ 1.5 x 10^9/L, platelet count ≥ 100 x 10^9/L
Kidney function
serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min
Liver function
total bilirubin < 1.5 x ULN (if >1.5 x ULN, direct bilirubin must ≤ ULN), AST and ALT ≤2.5 ULN
Adequate organ function within 1 week prior to enrollment: Adequate bone marrow function: hemoglobin ≥80g/L, WBC ≥ 4.0 x 10^9/L or neutrophil count ≥ 1.5 x 10^9/L, and platelet count ≥ 100 x 10^9/L; Adequate hepatic function: total bilirubin < 1.5 x ULN. Note: If total bilirubin is > 1.5 x ULN, direct bilirubin must ≤ ULN, AST and ALT ≤2.5 ULN; Adequate renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify